We aimed to compare the diagnostic performance of PET/CT imaging performed with 68Ga-DOTA-FAPI and 18FDG in detection of liver metastases in patients with gastrointestinal system (GIS) cancer. MethodsA total of 31 patients who underwent 68 Ga-DOTA-FAPI and 18 F-FDG PET/CT examinations and diagnosed with GIS cancer (15 colorectal, 9 pancreas, 4 stomach and 3 other cancers) were included in the study. The presence of liver metastasis was decided based on histopathologic diagnosis, PET/CT, other radiologic examinations or tumor biomarker ndings, and both PET/CT imaging ndings were compared on the patient and lesion basis. ResultsOf the 31 patients, 28 were found as true positive with 68 Ga-DOTA-FAPI-PET/CT and 17 with 18 FDG-PET/CT. Of the 98 metastatic liver lesions determined according to our diagnostic criteria, 92 were found as true positive lesions with 68 Ga-DOTA-FAPI-PET/CT and 65 with 18 FDG-PET/CT. There was a statistically signi cant difference between both imaging modalities in the patient and lesion based comparisons (p<0.05).When semiquantitative values (SUVmax, mlr) obtained from the lesions were compared between the two imaging methods, mlr values showed statistically signi cant difference in all tumor subgroups (p<0.05). ConclusionIt was concluded that 68 Ga-DOTA-FAPI-PET/CT was superior over 18 FDG-PET/CT in detection of liver metastases of GIS cancers and it can be a complementary method especially in negative cases with 18 FDG-PET/CT.

No abstract

<b><i>Background:</i></b> Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. In the current study, we compare these three age groups. <b><i>Methods:</i></b>A total of 173 (1.1% of 15,654 patients) young CRC patients (≤25 years) were included in the study. As a control group, 237 adult CRC patients (&#x3e;25 years) were also included. Patients were divided into three age groups: child/adolescent (10–19 years), young adult (20–25 years), and adult (&#x3e;25 years). <b><i>Results:</i></b> Statistical differences amongst the three groups in terms of gender (<i>p</i> = 0.446), family history (<i>p</i> = 0.578), symptoms of presentation (<i>p</i> = 0.306), and interval between initiation of symptoms and diagnosis (<i>p</i> = 0.710) could not be demonstrated. Whilst abdominal pain (<i>p</i> &#x3c; 0.001) and vomiting (<i>p</i> = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (<i>p</i> = 0.035), mucinous adenocarcinoma (<i>p</i> &#x3c; 0.001), and a poorly differentiated histologic subtype (<i>p</i> &#x3c; 0.001) were less common in the adult group than in other groups. The percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. The median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (<i>p</i> = 0.022). The median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (<i>p</i> = 0.003). <b><i>Conclusions:</i></b> CRC patients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences.

PurposeWe aimed to compare the diagnostic performance of PET/CT imaging performed with 68Ga-DOTA-FAPI and 18FDG in detection of liver metastases in patients with gastrointestinal system (GIS) cancer.MethodsA total of 31 patients who underwent 68Ga-DOTA-FAPI and 18F-FDG PET/CT examinations and diagnosed with GIS cancer (15 colorectal, 9 pancreas, 4 stomach and 3 other cancers) were included in the study. The presence of liver metastasis was decided based on histopathologic diagnosis, PET/CT, other radiologic examinations or tumor biomarker findings, and both PET/CT imaging findings were compared on the patient and lesion basis. ResultsOf the 31 patients, 28 were found as true positive with 68Ga-DOTA-FAPI-PET/CT and 17 with 18FDG-PET/CT. Of the 98 metastatic liver lesions determined according to our diagnostic criteria, 92 were found as true positive lesions with 68Ga-DOTA-FAPI-PET/CT and 65 with 18FDG-PET/CT. There was a statistically significant difference between both imaging modalities in the patient and lesion based comparisons (p<0.05).When semiquantitative values (SUVmax, mlr) obtained from the lesions were compared between the two imaging methods, mlr values showed statistically significant difference in all tumor subgroups (p<0.05).ConclusionIt was concluded that 68Ga-DOTA-FAPI-PET/CT was superior over 18FDG-PET/CT in detection of liver metastases of GIS cancers and it can be a complementary method especially in negative cases with 18FDG-PET/CT.

No abstract